CommercialPrior AuthMedium impact
Solaraze 3% (diclofenac) Gel
Blue Cross & Blue Shield of Mississippi·MS · Dermatology, Family Medicine, Internal Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBSMS updated their Solaraze 3% (diclofenac) gel policy with new restrictions. Patient sample usage no longer counts toward meeting prior authorization requirements, and services related to delivery/administration of unapproved medications will be denied.
Action Required
Immediately: Update prior authorization documentation to exclude patient samples when demonstrating failed generic alternatives for Solaraze 3% gel. Billing team must ensure only pharmacy-dispensed medications are documented as trial failures for actinic keratosis treatments. Verify prior authorization approval before billing any delivery or administration services for this medication to avoid denials.